The data indicate that appropriate iron supplementation might be a potential strategy in the treatment of HPH, and that therapies targeting energy metabolism by inhibiting HIF2α activation may also be beneficial if iron deficiency status persists or fails to improve. The gene discussed is EPAS1; the disease is Iron deficiency anemia.